Literature DB >> 2493434

Definitive radiotherapy for squamous cell carcinoma of the tonsillar fossa.

C S Wong1, K K Ang, G H Fletcher, H D Thames, L J Peters, R M Byers, M J Oswald.   

Abstract

Between July 1968 and December 1983, 150 patients with previously untreated squamous cell carcinomas of the tonsillar fossa received megavoltage external beam irradiation with curative intent at U.T.M.D. Anderson Cancer Center. These patients were treated following a series of patients who had received radiotherapy between 1954 and May 1968. One hundred and thirty-seven patients were treated with conventional fractionation, the mean doses to the primary being 64.3 Gy, 67.8 Gy, 70.2 Gy, and 72.6 Gy for T1, T2, T3, and T4 lesions respectively. Thirteen patients were treated by altered fractionation schedules, 7 by hyperfractionation, and 6 by a concomitant boost to the primary. Elective bilateral neck irradiation was routine in all patients. A planned neck dissection was performed in 26 patients. The 5-year actuarial overall and disease-specific survival rates were 47% and 70%, respectively. Absolute local control rates with a minimum of 2 years follow-up after irradiation were 94%, 79%, 58%, and 50% for patients with T1, T2, T3, and T4 disease respectively. A total of 37 patients had local treatment failure; in 5 of 18 surgical salvage was successful. Only 4 patients with primary disease control developed failure in the neck and none of those with N0 or N1 disease did so when the primary was controlled. Twelve patients developed transient self-limited bone exposure, 7 developed osteoradionecrosis of the mandible, all requiring surgical resection. Most severe late complications occurred in patients with T3 and T4 lesions whose dose to the primary exceeded 67.5 Gy.

Entities:  

Mesh:

Year:  1989        PMID: 2493434     DOI: 10.1016/0360-3016(89)90481-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival.

Authors:  Christian Simon; Helmuth Goepfert; David I Rosenthal; Dianna Roberts; Adel El-Naggar; Matthew Old; Eduardo M Diaz; Jeffrey N Myers
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-11-22       Impact factor: 2.503

2.  Radiotherapy alone or combined with chemotherapy as definitive treatment for squamous cell carcinoma of the tonsil.

Authors:  William R Kennedy; Michael P Herman; Rohan L Deraniyagala; Robert J Amdur; John W Werning; Peter Dziegielewski; Jessica Kirwan; Christopher G Morris; William M Mendenhall
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-08       Impact factor: 2.503

3.  Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer.

Authors:  Adam S Garden; Clifton D Fuller; David I Rosenthal; William N William; Gary B Gunn; Beth M Beadle; Faye M Johnson; William H Morrison; Jack Phan; Steven J Frank; Merrill S Kies; Erich M Sturgis
Journal:  Cancer       Date:  2016-03-28       Impact factor: 6.860

4.  Long-term outcome analysis after surgical salvage for recurrent tonsil carcinoma following radical radiotherapy.

Authors:  Gideon Y Bachar; Christopher Goh; David P Goldstein; Brian O'Sullivan; Jonathan C Irish
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-02       Impact factor: 2.503

5.  Tonsillar carcinoma.

Authors:  M E Guay; P Lavertu
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

6.  Candidate silencer elements for the human and mouse genomes.

Authors:  Naresh Doni Jayavelu; Ajay Jajodia; Arpit Mishra; R David Hawkins
Journal:  Nat Commun       Date:  2020-02-26       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.